Should not be given with lactulose or other drugs which lower pH thereby preventing release of mesalazine.

NSAIDs . Coumarin anti-coagulants
Sulphonyl ureas, methotrexate probenicid
Azathioprine, Sulphinpyrazone, Sulphanolactone
Frusemide, rifampicin, glucocorticoids

Lab test abnormalities:
Elevated AST,ALT, alkaline phophatase, serum creatinine, BUN, amylase,lipase,GGTP, and LDH.

 

Ulcerative colitis Crohns colitis or ileocolitis

Sinusitis, interstital pneumonitis, asthma exacerabations, pulmonary infiltrates.

Pericarditis, myocarditis, vasodilations.  

Anxiety, depression, somnolence, emotional lability,

Vertigo, nervousness, confusion, parathesia, tremor.

 Anorexia, pancreatitis, gastritis

 

Hypersensitivity to mesalamine, salicylates
Salicylate hpersensitivity or renal sensitivity to sulphasalazine

Severe renal or hepatic impairment
Active peptic ulcer

Bleeding tendencies
Blood clotting anbormalities

Special precautions:
Lactation,pregnancy,children,renal/hepatic dysfunction.
Hepatic impairment

Monitor renal function before and periodically during treatment
Maintain adequate hydration

Raised blood urea or proteinuria
Advice patients to report unusal bleeding

 

Approved on   2002

Indications:
Chronic inflammatory bowel disease
Dosage:
Oral- tablets-  800mg 3 times daily for a total dose of 2.4g/day for 6 weeks
Capsules-  1g 4 times daily for a total dose of 4g for upto 8 weeks

Overdosage-

                               Symptoms                                            

Symptoms of salicylate toxicity may be possible. Such as tinnitus, vertigo, headache, confusion,  drowsiness, sweating, hyperventilation, vomiting and                  diarrhea.                                                               
Severe intoxification with salicylates can lead to disruption of electrolyte balance and blood pH,  hyperthermia and dehyratation.                                       

                                Treatment

1. Conventinal therapy of salicylate toxicity may be beneficial  in the event of acute overdosage.

2. This includes prevention of further GI tract absorption by emesis and if necessary by gastric lavage

3. Correct fluid and electrolyte imbalance by the administration  of appropriate IV therapy

 4. Maintain adequate renal function.


Missed dose-
1. If you miss a dose of this medicine, take it as soon as possible.
2. However, if it is almost time for next dose, skip the missed dose and go back to your regular dosing
   schedule.
3. Do not double doses.

 

REFER 5amino salicylic acid- ASA or Mesalamine

REFER- 5 amio salicylic  0r ASA or Mesalamine


1. Tablets- swallow tablets whole, do not break the outer coating, which is designed to remain   intact to protect the active ingredient. In 2 to 3% of patients, intact or partially intact tablets are    found in the stool. If this occurs, inform the physician

 

Pharmacology:
Sulfasalazine is split by bacterial action in the colon into sulfapyridine (SP) and messalamine
(5-ASA). It is thought that the mesalamine component is therapeutically active in ulcerative colitis.
The mechanism of action is unknown, but appears to be topical than systemic.

Pharmacokinetics:
Mesalamine administered rectally as a suspension enema is poorly absorbed from the colon
and is excreted principally in the feces during subsequent bowel movements.

 

Pregnancy:
Use during only if needed.

Lactation:
Excercise caution while administering to a nursing woman.